<topic id="PHP79652" outputclass="clinicalMedicinalProductInformation">
    <title>Cardioxane<tm tmtype="reg"/></title>
    <topic id="PHP79722" outputclass="indicationsAndDose">
     <title>Indications and dose</title>
     <body>
      <section outputclass="indicationAndDoseGroup"><sectiondiv outputclass="therapeuticIndications"
         ><p outputclass="therapeuticIndication">Prevention of chronic cumulative cardiotoxicity
         caused by doxorubicin or epirubicin treatment in advanced or metastatic breast cancer
         patients who have received a prior cumulative dose of 300 mg/m² of doxorubicin or a prior
         cumulative dose of 540 mg/m² of epirubicin when further anthracycline treatment is
         required</p>
       </sectiondiv><p outputclass="routesOfAdministration">By intravenous infusion</p><ul
        outputclass="patientGroups">
        <li outputclass="patientGroup adult"><p>Adult</p><p>Administer 10 times the
          doxorubicin-equivalent dose or 10 times the epirubicin-equivalent dose, dose to be given
          30 minutes before anthracycline administration.</p>
        </li>
       </ul>
      </section>
     </body>
    </topic>
    <topic id="PHP79701" outputclass="cautions">
     <title>Cautions</title>
     <body>
      <section outputclass="cautions"><p><ph outputclass="caution">Manufacturer advises caution in
         patients with heart failure—no information available</ph>; <ph outputclass="caution"
         >manufacturer advises caution in patients with myocardial infarction in previous 12
         months—no information available</ph>; <ph outputclass="caution">manufacturer advises
         caution in patients with symptomatic valvular heart disease—no information available</ph>;
         <ph outputclass="caution">manufacturer advises caution in patients with uncontrolled
         angina—no information available</ph></p>
      </section>
     </body>
    </topic>
    <topic id="PHP79763" outputclass="sideEffects">
     <title>Side-effects</title>
     <body>
      <section outputclass="frequencies"><sectiondiv outputclass="commonOrVeryCommon"><p
         outputclass="title">Common or very common</p><sectiondiv outputclass="sideEffects"><p><ph
           outputclass="sideEffect">Anorexia</ph>; <ph outputclass="sideEffect">asthenia</ph>; <ph
           outputclass="sideEffect">diarrhoea</ph>; <ph outputclass="sideEffect">dizziness</ph>; <ph
           outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">dyspnoea</ph>; <ph
           outputclass="sideEffect">erythema</ph>; <ph outputclass="sideEffect">infection</ph>; <ph
           outputclass="sideEffect">malaise</ph>; <ph outputclass="sideEffect">nausea</ph>; <ph
           outputclass="sideEffect">oedema</ph>; <ph outputclass="sideEffect">paraesthesia</ph>; <ph
           outputclass="sideEffect">peripheral neuropathy</ph>; <ph outputclass="sideEffect"
           >stomatitis</ph>; <ph outputclass="sideEffect">syncope</ph>; <ph outputclass="sideEffect"
           >vomiting</ph></p>
        </sectiondiv>
       </sectiondiv><sectiondiv outputclass="uncommon"><p outputclass="title"
         >Uncommon</p><sectiondiv outputclass="sideEffects"><p><ph outputclass="sideEffect"
           >Abdominal pain</ph>; <ph outputclass="sideEffect">acute myeloid leukaemia</ph>; <ph
           outputclass="sideEffect">constipation</ph>; <ph outputclass="sideEffect">cough</ph>; <ph
           outputclass="sideEffect">dyspepsia</ph>; <ph outputclass="sideEffect">headache</ph>; <ph
           outputclass="sideEffect">lymphoedema</ph>; <ph outputclass="sideEffect">nail
           disorder</ph>; <ph outputclass="sideEffect">reduced ejection fraction</ph>; <ph
           outputclass="sideEffect">tachycardia</ph>; <ph outputclass="sideEffect">thromboembolism
           (when given with cytotoxic drugs)</ph></p>
        </sectiondiv>
       </sectiondiv><sectiondiv outputclass="notKnown"><p outputclass="title">Frequency not
         known</p><sectiondiv outputclass="sideEffects"><p><ph outputclass="sideEffect"
           >Alopecia</ph>; <ph outputclass="sideEffect">anaemia</ph>; <ph outputclass="sideEffect"
           >blood disorders</ph>; <ph outputclass="sideEffect">fatigue</ph>; <ph
           outputclass="sideEffect">injection-site reactions</ph>; <ph outputclass="sideEffect"
           >leucopenia</ph>; <ph outputclass="sideEffect">phlebitis</ph>; <ph
           outputclass="sideEffect">pruritus</ph>; <ph outputclass="sideEffect">pyrexia</ph>; <ph
           outputclass="sideEffect">thrombocytopenia</ph></p>
        </sectiondiv>
       </sectiondiv>
      </section>
     </body>
    </topic>
    <topic id="PHP79726" outputclass="hepaticImpairment">
     <title>Hepatic impairment</title>
     <body>
      <section outputclass="doseAdjustments"><sectiondiv><p>Manufacturer advises that if
         anthracycline dose is reduced, reduce the <i>Cardioxane</i><tm tmtype="reg"/> dose by a
         similar ratio.</p>
       </sectiondiv>
      </section>
     </body>
    </topic>
    <topic id="PHP79733" outputclass="renalImpairment">
     <title>Renal impairment</title>
     <body>
      <section outputclass="doseAdjustments"><sectiondiv><p>Manufacturer advises reduce dose by 50%
         if creatinine clearance less than 40 mL/minute.</p>
       </sectiondiv>
      </section>
     </body>
    </topic>
    <topic id="PHP79782" outputclass="directionsForAdministration">
     <title>Directions for administration</title>
     <body>
      <section><sectiondiv><p>For <i>intravenous infusion</i>, give intermittently <i>in</i>
         Compound sodium lactate; reconstitute each vial with 25 mL water for injections and dilute
         each vial with 25–100 mL infusion fluid; give requisite dose over 15 minutes.</p>
       </sectiondiv>
      </section>
     </body>
    </topic>
   </topic>
